Ardelyx Funding & Investors
Ardelyx, Inc. manufactures biotechnological drugs. The Company offers pharmaceuticals to correct mineral metabolism imbalance and metabolic disorders by modulating the function of specific transporters, channels, and receptors located on the epithelia of the gastrointestinal tract. Ardelyx serves patients in the United States.
ardelyx.comTotal Amount Raised: $291,361,600
Ardelyx Funding Rounds
Post Ipo Debt
$20,000,000
Post Ipo Debt Investors
HealthCare Royalty PartnersKyowa Kirin Co.Post Ipo Debt
$27,500,000
Post Ipo Debt Investors
SLR Capital PartnersPost Ipo Equity
$110,000,000
Post Ipo Equity Investors
New Enterprise Associates (NEA)Quadrille CapitalEcoR1 CapitalRa Capital ManagementFirst Manhattan Consulting GroupRock Springs CapitalCormorant Asset ManagementPerceptive AdvisorsDeerfield ManagementDAFNA Capital ManagementPost Ipo Equity
$77,771,627
Post Ipo Equity Investors
New Enterprise Associates (NEA)Ra Capital ManagementBroadfin CapitalCormorant Asset ManagementForesite CapitalRock Springs CapitalSabby CapitalPost Ipo Equity
$77,771,627
Post Ipo Equity Investors
New Enterprise Associates (NEA)Ra Capital ManagementBroadfin CapitalCormorant Asset ManagementForesite CapitalRock Springs CapitalSabby CapitalSeries B
$30,000,000
Series B Investors
Amgen VenturesCMEA CapitalNew Enterprise Associates (NEA)Series B
$30,000,000
Series B Investors
Amgen VenturesCMEA CapitalNew Enterprise Associates (NEA)Series A
$26,090,000
Series A Investors
CMEA Capital
Funding info provided by Diffbot.